

David Tougeron

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6255311/publications.pdf>

Version: 2024-02-01

208
papers

5,844
citations

101384

36
h-index

91712

69
g-index

228
all docs

228
docs citations

228
times ranked

9301
citing authors

#	ARTICLE	IF	CITATIONS
1	Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability. <i>Immunity</i> , 2016, 44, 698-711.	6.6	814
2	Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE) Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 658-667.	0.8	357
3	Correlation between Density of CD8+ T-cell Infiltrate in Microsatellite Unstable Colorectal Cancers and Frameshift Mutations: A Rationale for Personalized Immunotherapy. <i>Cancer Research</i> , 2015, 75, 3446-3455.	0.4	210
4	Radioembolization Plus Chemotherapy for First-line Treatment of Locally Advanced Intrahepatic Cholangiocarcinoma. <i>JAMA Oncology</i> , 2020, 6, 51.	3.4	176
5	Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after FOLFIRINOX failure: an AGEO prospective multicentre cohort. <i>British Journal of Cancer</i> , 2015, 113, 989-995.	2.9	151
6	RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study. <i>Annals of Oncology</i> , 2018, 29, 1211-1219.	0.6	136
7	Tumor-infiltrating lymphocytes in colorectal cancers with microsatellite instability are correlated with the number and spectrum of frameshift mutations. <i>Modern Pathology</i> , 2009, 22, 1186-1195.	2.9	132
8	Chemotherapy of advanced small-bowel adenocarcinoma: a multicenter AGEO study. <i>Annals of Oncology</i> , 2010, 21, 1786-1793.	0.6	132
9	KRAS Codon 12 and 13 Mutations in Relation to Disease-Free Survival in BRAF Wild-Type Stage III Colon Cancers from an Adjuvant Chemotherapy Trial (N0147 Alliance). <i>Clinical Cancer Research</i> , 2014, 20, 3033-3043.	3.2	129
10	Efficacy of Adjuvant Chemotherapy in Colon Cancer With Microsatellite Instability: A Large Multicenter AGEO Study. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv438.	3.0	127
11	Microsatellite Instability: Diagnosis, Heterogeneity, Discordance, and Clinical Impact in Colorectal Cancer. <i>Cancers</i> , 2019, 11, 1567.	1.7	114
12	Safety and outcome of definitive chemoradiotherapy in elderly patients with oesophageal cancer. <i>British Journal of Cancer</i> , 2008, 99, 1586-1592.	2.9	105
13	Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer. <i>Annals of Oncology</i> , 2013, 24, 1267-1273.	0.6	96
14	Second-line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine-platinum combination: A large multicenter study by the Association des Gastro-entérologues Oncologues. <i>Cancer</i> , 2015, 121, 3290-3297.	2.0	95
15	Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program. <i>BMC Cancer</i> , 2016, 16, 412.	1.1	89
16	TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy. <i>British Journal of Cancer</i> , 2009, 100, 1330-1335.	2.9	86
17	Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort. <i>European Journal of Cancer</i> , 2017, 79, 158-165.	1.3	84
18	Metastatic colorectal cancer (mCRC): French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR). <i>Digestive and Liver Disease</i> , 2019, 51, 1357-1363.	0.4	80

#	ARTICLE	IF	CITATIONS
19	Usefulness of the Serum Carcinoembryonic Antigen Kinetic for Chemotherapy Monitoring in Patients With Unresectable Metastasis of Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 3681-3686.	0.8	77
20	Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001â€“02). <i>Annals of Oncology</i> , 2016, 27, 121-127.	0.6	76
21	Secondâ€“line chemotherapy with fluorouracil, leucovorin, and irinotecan (FOLFIRI regimen) in patients with advanced small bowel adenocarcinoma after failure of firstâ€“line platinumâ€“based chemotherapy. <i>Cancer</i> , 2011, 117, 1422-1428.	2.0	71
22	Predicting Factors of Fistula Healing and Clinical Remission After Infliximab-Based Combined Therapy for Perianal Fistulizing Crohnâ€™s Disease. <i>Digestive Diseases and Sciences</i> , 2009, 54, 1746-1752.	1.1	68
23	Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial. <i>European Journal of Cancer</i> , 2020, 124, 91-101.	1.3	68
24	A Diagnostic Biopsy-Adapted Immunoscore Predicts Response to Neoadjuvant Treatment and Selects Patients with Rectal Cancer Eligible for a Watch-and-Wait Strategy. <i>Clinical Cancer Research</i> , 2020, 26, 5198-5207.	3.2	66
25	Mutationâ€“specific antibody detects mutant BRAF^{V600E} protein expression in human colon carcinomas. <i>Cancer</i> , 2013, 119, 2765-2770.	2.0	60
26	Aspirin and Colorectal Cancer: Back to the Future. <i>Clinical Cancer Research</i> , 2014, 20, 1087-1094.	3.2	58
27	Results and challenges of immune checkpoint inhibitors in colorectal cancer. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 561-573.	1.4	58
28	Small bowel adenocarcinoma: Results from a nationwide prospective ARCADâ€“NADEGE cohort study of 347 patients. <i>International Journal of Cancer</i> , 2020, 147, 967-977.	2.3	57
29	Beclin 1 and UVRAG Confer Protection from Radiation-Induced DNA Damage and Maintain Centrosome Stability in Colorectal Cancer Cells. <i>PLoS ONE</i> , 2014, 9, e100819.	1.1	57
30	Prognosis and chemosensitivity of deficient MMR phenotype in patients with metastatic colorectal cancer: An AGEO retrospective multicenter study. <i>International Journal of Cancer</i> , 2020, 147, 285-296.	2.3	56
31	Anti program death-1/anti program death-ligand 1 in digestive cancers. <i>World Journal of Gastrointestinal Oncology</i> , 2015, 7, 95.	0.8	53
32	Temozolomide Alone or Combined with Capecitabine for the Treatment of Advanced Pancreatic Neuroendocrine Tumor. <i>Neuroendocrinology</i> , 2020, 110, 83-91.	1.2	44
33	RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study. , 2020, 8, e001499.		43
34	Discordance between immunochemistry of mismatch repair proteins and molecular testing of microsatellite instability in colorectal cancer. <i>ESMO Open</i> , 2021, 6, 100120.	2.0	42
35	Association between clinicopathological characteristics and RAS mutation in colorectal cancer. <i>Modern Pathology</i> , 2018, 31, 517-526.	2.9	41
36	MSH3 Mismatch Repair Protein Regulates Sensitivity to Cytotoxic Drugs and a Histone Deacetylase Inhibitor in Human Colon Carcinoma Cells. <i>PLoS ONE</i> , 2013, 8, e65369.	1.1	41

#	ARTICLE	IF	CITATIONS
37	ABCB4/MDR3 gene mutations and cholangiocarcinomas. <i>Journal of Hepatology</i> , 2012, 57, 467-468.	1.8	40
38	FOLFIRINOX versus gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: a comparative propensity score study. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 175628481987866.	1.4	39
39	Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in patients (pts) with localized microsatellite instability-high (MSI)/mismatch repair deficient (dMMR) oeso-gastric adenocarcinoma (OGA): The GERCOR NEONIPGA phase II study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 244-244.	0.8	39
40	High plasma levels of the pro-inflammatory cytokine IL-22 and the anti-inflammatory cytokines IL-10 and IL-1ra in acute pancreatitis. <i>Pancreatology</i> , 2014, 14, 465-469.	0.5	37
41	Gemcitabine plus platinum-based chemotherapy for first-line treatment of hepatocholangiocarcinoma: an AGEO French multicentre retrospective study. <i>British Journal of Cancer</i> , 2018, 118, 325-330.	2.9	37
42	Esophageal cancer in the elderly: an analysis of the factors associated with treatment decisions and outcomes. <i>BMC Cancer</i> , 2010, 10, 510.	1.1	36
43	Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations. <i>European Journal of Cancer</i> , 2019, 111, 94-106.	1.3	36
44	High Intra- and Inter-Tumoral Heterogeneity of RAS Mutations in Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2016, 17, 2015.	1.8	35
45	Comparison of Temozolomide-Capecitabine to 5-Fluorouracile-Dacarbazine in 247 Patients with Advanced Digestive Neuroendocrine Tumors Using Propensity Score Analyses. <i>Neuroendocrinology</i> , 2019, 108, 343-353.	1.2	34
46	Triplet combination of durvalumab, tremelimumab, and paclitaxel in biliary tract carcinomas: Safety run-in results of the randomized IMMUNOBIL PRODIGE 57 phase II trial. <i>European Journal of Cancer</i> , 2021, 143, 55-63.	1.3	32
47	Trastuzumab beyond progression in patients with HER2-positive advanced gastric adenocarcinoma: a multicenter AGEO study. <i>Oncotarget</i> , 2017, 8, 101383-101393.	0.8	31
48	Safety and outcome of chemoradiotherapy in elderly patients with rectal cancer: Results from two French tertiary centres. <i>Digestive and Liver Disease</i> , 2012, 44, 350-354.	0.4	30
49	Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials. <i>European Journal of Cancer</i> , 2018, 98, 1-9.	1.3	30
50	Geriatric analysis from PRODIGE 20 randomized phase II trial evaluating bevacizumab+chemotherapy versus chemotherapy alone in older patients with untreated metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2018, 97, 16-24.	1.3	30
51	Microsatellite Instability in Colorectal Cancers: Carcinogenesis, Neo-Antigens, Immuno-Resistance and Emerging Therapies. <i>Cancers</i> , 2021, 13, 3063.	1.7	29
52	Radiochemotherapy Versus Surgery in Nonmetastatic Anorectal Neuroendocrine Carcinoma. <i>Medicine (United States)</i> , 2015, 94, e1864.	0.4	28
53	Professional risks when carrying out cytoreductive surgery for peritoneal malignancy with hyperthermic intraperitoneal chemotherapy (HIPEC): A French multicentric survey. <i>European Journal of Surgical Oncology</i> , 2015, 41, 1361-1367.	0.5	28
54	Randomized study to investigate FOLFOXIRI plus either bevacizumab or cetuximab as first-line treatment of BRAF V600E-mutant mCRC: The phase-II FIRE-4.5 study (AIO KRK-0116).. <i>Journal of Clinical Oncology</i> , 2021, 39, 3502-3502.	0.8	28

#	ARTICLE	IF	CITATIONS
55	Heterogeneity of mismatch repair defect in colorectal cancer and its implications in clinical practice. <i>European Journal of Cancer</i> , 2018, 95, 112-116.	1.3	26
56	A panel of stomach-specific biomarkers (GastroPanel®) for the diagnosis of atrophic gastritis: A prospective, multicenter study in a low gastric cancer incidence area. <i>Helicobacter</i> , 2020, 25, e12727.	1.6	25
57	Predictors of disease-free survival in colorectal cancer with microsatellite instability: An AGEO multicentre study. <i>European Journal of Cancer</i> , 2015, 51, 925-934.	1.3	24
58	Resection of small bowel adenocarcinoma metastases: Results of the ARCAD-NADEGE cohort study. <i>European Journal of Surgical Oncology</i> , 2019, 45, 331-335.	0.5	24
59	Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial. <i>BMC Cancer</i> , 2020, 20, 352.	1.1	24
60	Does neoadjuvant FOLFOX chemotherapy improve the prognosis of high-risk Stage II and III colon cancers? Three years' follow-up results of the PRODIGE 22 phase II randomized multicentre trial. <i>Colorectal Disease</i> , 2021, 23, 1357-1369.	0.7	23
61	Efficacy of a docetaxel-5FU-oxaliplatin regimen (TEFOX) in first-line treatment of advanced gastric signet ring cell carcinoma: an AGEO multicentre study. <i>British Journal of Cancer</i> , 2018, 119, 424-428.	2.9	22
62	BRAF Mutation Status in Circulating Tumor DNA from Patients with Metastatic Colorectal Cancer: Extended Mutation Analysis from the AGEO RASANC Study. <i>Cancers</i> , 2019, 11, 998.	1.7	22
63	Regulatory T Lymphocytes Are Associated with Less Aggressive Histologic Features in Microsatellite-Unstable Colorectal Cancers. <i>PLoS ONE</i> , 2013, 8, e61001.	1.1	22
64	Response to Definitive Chemoradiotherapy and Survival in Patients with an Oesophageal Adenocarcinoma versus Squamous Cell Carcinoma: A Matched-Pair Analysis. <i>Oncology</i> , 2007, 73, 328-334.	0.9	21
65	Colonoscopy uptake for high-risk individuals with a family history of colorectal neoplasia. <i>Medicine (United States)</i> , 2016, 95, e4303.	0.4	21
66	Panel gene profiling of small bowel adenocarcinoma: Results from the NADEGE prospective cohort. <i>International Journal of Cancer</i> , 2021, 148, 1731-1742.	2.3	21
67	Characteristics of BRAF V600E Mutant, Deficient Mismatch Repair/Proficient Mismatch Repair, Metastatic Colorectal Cancer: A Multicenter Series of 287 Patients. <i>Oncologist</i> , 2019, 24, e1331-e1340.	1.9	20
68	Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: update of the AGEO cohort. <i>British Journal of Cancer</i> , 2021, 124, 1941-1948.	2.9	20
69	Association of beclin 1 expression with response to neoadjuvant chemoradiation therapy in patients with locally advanced rectal carcinoma. <i>International Journal of Cancer</i> , 2015, 137, 1498-1502.	2.3	19
70	Irreversible electroporation for locally advanced pancreatic cancer. <i>Diagnostic and Interventional Imaging</i> , 2016, 97, 1297-1304.	1.8	19
71	Pathological and Molecular Characteristics of Colorectal Cancer with Brain Metastases. <i>Cancers</i> , 2018, 10, 504.	1.7	18
72	Decision for adjuvant treatment in stage II colon cancer based on circulating tumor DNA: The CIRCULATE-PRODIGE 70 trial. <i>Digestive and Liver Disease</i> , 2020, 52, 730-733.	0.4	18

#	ARTICLE	IF	CITATIONS
73	HLA-A*0201-restricted CEA-derived Peptide CAP1 Is Not a Suitable Target for T-cell-based Immunotherapy. <i>Journal of Immunotherapy</i> , 2010, 33, 402-413.	1.2	17
74	Efficacy of modern chemotherapy and prognostic factors in patients with ovarian metastases from gastric cancer: A retrospective AGEO multicentre study. <i>Digestive and Liver Disease</i> , 2016, 48, 441-445.	0.4	17
75	Fluoropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer. <i>International Journal of Cancer</i> , 2020, 147, 3177-3188.	2.3	17
76	Future perspectives of circulating tumor DNA in colorectal cancer. <i>Tumor Biology</i> , 2017, 39, 101042831770574.	0.8	16
77	Detection of Colorectal Cancer and Advanced Adenoma by Liquid Biopsy (Decalib Study): The ddPCR Challenge. <i>Cancers</i> , 2020, 12, 1482.	1.7	16
78	Intra-arterial hepatic beads loaded with irinotecan (DEBIRI) with mFOLFOX6 in unresectable liver metastases from colorectal cancer: a Phase 2 study. <i>British Journal of Cancer</i> , 2020, 123, 518-524.	2.9	16
79	Unusual skeletal muscle metastasis from gastric adenocarcinoma. <i>Gastroenterologie Clinique Et Biologique</i> , 2009, 33, 485-487.	0.9	15
80	Epidermal growth factor receptor (EGFR) and KRAS mutations during chemotherapy plus anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 397-403.	1.1	15
81	Phase III randomized trial comparing 5-fluorouracil and oxaliplatin with or without docetaxel in first-line advanced gastric cancer chemotherapy (GASTFOX study). <i>Digestive and Liver Disease</i> , 2018, 50, 408-410.	0.4	14
82	Intra peritoneal abdominal fat area measured from computed tomography is an independent factor of severe acute pancreatitis. <i>Diagnostic and Interventional Imaging</i> , 2019, 100, 421-426.	1.8	14
83	Where to Biopsy to Detect <i>Helicobacter pylori</i> and How Many Biopsies Are Needed to Detect Antibiotic Resistance in a Human Stomach. <i>Journal of Clinical Medicine</i> , 2020, 9, 2812.	1.0	14
84	Avelumab versus standard second line treatment chemotherapy in metastatic colorectal cancer patients with microsatellite instability: The SAMCO-PRODIGE 54 randomised phase II trial. <i>Digestive and Liver Disease</i> , 2021, 53, 318-323.	0.4	14
85	Definitive chemoradiotherapy in patients with esophageal adenocarcinoma: An alternative to surgery?. <i>Journal of Surgical Oncology</i> , 2012, 105, 761-766.	0.8	13
86	Aspirin versus placebo in stage III or high-risk stage II colon cancer with PIK3CA mutation: A French randomised double-blind phase III trial (PRODIGE 50-ASPIK). <i>Digestive and Liver Disease</i> , 2018, 50, 305-307.	0.4	13
87	Three fluoropyrimidine-based regimens in routine clinical practice after nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: An AGEO multicenter study. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2020, 44, 295-301.	0.7	13
88	One-year duration of nivolumab plus ipilimumab in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI/dMMR) metastatic colorectal cancer (mCRC): Long-term follow-up of the GERCOR NIPICOL phase II study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 13-13.	0.8	12
89	Management of esophageal adenocarcinoma. <i>Journal of Visceral Surgery</i> , 2011, 148, e161-e170.	0.4	11
90	Irreversible Electroporation for Locally Advanced Pancreatic Cancer. <i>Pancreas</i> , 2017, 46, 283-287.	0.5	11

#	ARTICLE	IF	CITATIONS
91	Severe acute respiratory syndrome coronavirus 2 vaccination for patients with solid cancer: Review and point of view of a French oncology intergroup (GCO, TNCD, UNICANCER). <i>European Journal of Cancer</i> , 2021, 150, 232-239.	1.3	11
92	Treatments after Immune Checkpoint Inhibitors in Patients with dMMR/MSI Metastatic Colorectal Cancer. <i>Cancers</i> , 2022, 14, 406.	1.7	11
93	Impact of the COVID-19 pandemic on disease stage and treatment for patients with pancreatic adenocarcinoma: A French comprehensive multicentre ambispective observational cohort study (CAPANCOVID). <i>European Journal of Cancer</i> , 2022, 166, 8-20.	1.3	11
94	PRODIGE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI + Durvalumab ± Tremelimumab in second-line of patients with advanced gastric cancer. <i>Digestive and Liver Disease</i> , 2021, 53, 420-426.	0.4	10
95	Trybeca-1: A randomized, phase 3 study of eriyaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with advanced pancreatic adenocarcinoma (NCT03665441).. <i>Journal of Clinical Oncology</i> , 2022, 40, 518-518.	0.8	10
96	Rebecca: a Large Cohort Study of Regorafenib (Reg) in the Real-Life Setting in Patients (Pts) Previously Treated for Metastatic Colorectal Cancer (Mcr). <i>Annals of Oncology</i> , 2014, 25, iv205.	0.6	9
97	Clinical outcome of portal vein thrombosis in patients with digestive cancers: A large AGEO multicenter study. <i>Digestive and Liver Disease</i> , 2018, 50, 285-290.	0.4	9
98	Efficacy and Safety of Aflibercept in Combination With Chemotherapy Beyond Second-Line Therapy in Metastatic Colorectal Carcinoma Patients: An AGEO Multicenter Study. <i>Clinical Colorectal Cancer</i> , 2020, 19, 39-47.e5.	1.0	9
99	Prognostic factors of colorectal cancer patients with brain metastases. <i>Radiotherapy and Oncology</i> , 2021, 158, 67-73.	0.3	9
100	FOLFIRINEC: a randomized phase II trial of mFOLFIRINOX vs platinum-etoposide for metastatic neuroendocrine carcinoma of gastroenteropancreatic or unknown origin. <i>Digestive and Liver Disease</i> , 2021, 53, 824-829.	0.4	9
101	Impact of adjuvant chemotherapy with 5-FU or FOLFOX in colon cancers with microsatellite instability: An AGEO multicenter study.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3508-3508.	0.8	9
102	<i>RAS</i> mutations concordance in circulating tumor DNA (ctDNA) and tissue in metastatic colorectal cancer (mCRC): RASANC, an AGEO prospective multicenter study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 11509-11509.	0.8	9
103	A large multicenter study evaluating prognosis and chemosensitivity of metastatic colorectal cancers with microsatellite instability.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3536-3536.	0.8	9
104	Cardiovascular events in chronic hepatitis C. <i>European Journal of Gastroenterology and Hepatology</i> , 2015, 27, 1286-1292.	0.8	8
105	Perioperative chemotherapy with FOLFOX in resectable gastroesophageal adenocarcinoma in real life practice: An AGEO multicenter retrospective study. <i>Digestive and Liver Disease</i> , 2016, 48, 1498-1502.	0.4	8
106	A large retrospective multicenter study evaluating prognosis and chemosensitivity of metastatic colorectal cancer with microsatellite instability. <i>Annals of Oncology</i> , 2017, 28, v180.	0.6	8
107	Trastuzumab in Combination with FOLFIRI in Patients with Advanced HER2-Positive Gastro-Esophageal Adenocarcinoma: A Retrospective Multicenter AGEO Study. <i>Targeted Oncology</i> , 2018, 13, 107-112.	1.7	8
108	Management of digestive cancers during the COVID-19 second wave: A French intergroup point of view (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFR). <i>Digestive and Liver Disease</i> , 2021, 53, 306-308.	0.4	8

#	ARTICLE	IF	CITATIONS
109	Curcumin and NCLX inhibitors share anti-tumoral mechanisms in microsatellite-instability-driven colorectal cancer. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, 284.	2.4	8
110	Control of pelvic symptoms in patients with rectal cancer and synchronous metastases. <i>Gastroenterologie Clinique Et Biologique</i> , 2009, 33, 1106-1113.	0.9	7
111	A rare case of mantle cell lymphoma as lymphomatous polyposis with widespread involvement of the digestive tract. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2011, 35, 74-78.	0.7	7
112	A Phase 2b of erasypase in combination with gemcitabine or FOLFOX as second-line therapy in patients with metastatic pancreatic adenocarcinoma (NCT02195180). <i>Annals of Oncology</i> , 2017, 28, v211.	0.6	7
113	Upper Gastrointestinal Lesions during Endoscopy Surveillance in Patients with Lynch Syndrome: A Multicentre Cohort Study. <i>Cancers</i> , 2021, 13, 1657.	1.7	7
114	Endoscopy to Diagnose and Prevent Digestive Cancers in Lynch Syndrome. <i>Cancers</i> , 2021, 13, 3505.	1.7	7
115	Prognostic Value of <i>Fusobacterium nucleatum</i> after Abdominoperineal Resection for Anal Squamous Cell Carcinoma. <i>Cancers</i> , 2022, 14, 1606.	1.7	7
116	Unusual iris metastasis from anal cancer: A case report. <i>Digestive and Liver Disease</i> , 2009, 41, e1-e3.	0.4	6
117	Absence of IDH mutation in colorectal cancers with microsatellite instability. <i>Digestive and Liver Disease</i> , 2016, 48, 681-683.	0.4	6
118	Nab paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after failure of folfirinox: Results of an AGEO multicenter prospective cohort.. <i>Journal of Clinical Oncology</i> , 2015, 33, 4123-4123.	0.8	6
119	Docetaxel, 5FU, oxaliplatin (TEFOX) in 1st line treatment of signet ring cell and/or poorly differentiated gastric adenocarcinoma: a retrospective study of AGEO.. <i>Journal of Clinical Oncology</i> , 2015, 33, e15048-e15048.	0.8	6
120	Heterogeneity of Mismatch Repair Status and Microsatellite Instability between Primary Tumour and Metastasis and Its Implications for Immunotherapy in Colorectal Cancers. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4427.	1.8	6
121	Skin inflammatory response and efficacy of anti-epidermal growth factor receptor therapy in metastatic colorectal cancer (CUTACETUX). <i>Oncolmmunology</i> , 2020, 9, 1848058.	2.1	5
122	Efficacy of Anti-EGFR in Microsatellite Instability Metastatic Colorectal Cancer Depending on Sporadic or Familial Origin. <i>Journal of the National Cancer Institute</i> , 2021, 113, 496-500.	3.0	5
123	Pembrolizumab with Capox Bevacizumab in patients with microsatellite stable metastatic colorectal cancer and a high immune infiltrate: The FFCO 1703-POCHI trial. <i>Digestive and Liver Disease</i> , 2021, 53, 1254-1259.	0.4	5
124	New Artificial Intelligence Score and Immune Infiltrates as Prognostic Factors in Colorectal Cancer With Brain Metastases. <i>Frontiers in Immunology</i> , 2021, 12, 750407.	2.2	5
125	Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO study. <i>British Journal of Cancer</i> , 2022, 126, 1394-1400.	2.9	5
126	Phase III randomized trial comparing systemic versus intra-arterial oxaliplatin, combined with LV5FU2 +/- irinotecan and a targeted therapy, in the first-line treatment of metastatic colorectal cancer restricted to the liver (OSCAR): PRODIGE 49. <i>Digestive and Liver Disease</i> , 2022, 54, 324-330.	0.4	5

#	ARTICLE	IF	CITATIONS
127	Sequential Treatment With Trifluridine/Tipiracil and Regorafenib in Refractory Metastatic Colorectal Cancer Patients: An AGEO Prospective "Real-World Study". <i>Clinical Colorectal Cancer</i> , 2022, 21, 132-140.	1.0	5
128	Small-bowel adenocarcinoma in patient with Crohn's disease: Report of a series of three cases. <i>Scandinavian Journal of Gastroenterology</i> , 2008, 43, 1397-1400.	0.6	4
129	Analysis of factors influencing molecular testing at diagnostic of colorectal cancer. <i>BMC Cancer</i> , 2017, 17, 765.	1.1	4
130	Th β 17 response and antimicrobial peptide expression are uniformly expressed in gastric mucosa of <i>Helicobacter pylori</i> -infected patients independently of their clinical outcomes. <i>Helicobacter</i> , 2018, 23, e12479.	1.6	4
131	AdvanTIG-203: A randomized phase 2 study comparing anti-TIGIT ociperlimab plus tislelizumab versus tislelizumab plus placebo as second-line treatment in patients with advanced or recurrent esophageal squamous cell carcinoma (ESCC) expressing programmed death-ligand 1 (PD-L1).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS4150-TPS4150.	0.8	4
132	Trastuzumab beyond progression in patients with HER2-positive advanced gastric adenocarcinoma: A multicenter AGEO study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 94-94.	0.8	4
133	Encorafenib plus cetuximab treatment in BRAF V600E-mutated metastatic colorectal cancer patients pre-treated with an anti-EGFR: An AGEO-GONO case series. <i>European Journal of Cancer</i> , 2022, 168, 34-40.	1.3	4
134	FFCD 1709-SIRTCl phase II trial: Selective internal radiation therapy plus Xelox, Bevacizumab and Atezolizumab in liver-dominant metastatic colorectal cancer. <i>Digestive and Liver Disease</i> , 2022, 54, 857-863.	0.4	4
135	Outcome of primary tumor in patients with synchronous stage IV colon or rectal cancer: So much the same yet so different. <i>Gastroenterologie Clinique Et Biologique</i> , 2010, 34, e15-e16.	0.9	3
136	Comment on "KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer". <i>British Journal of Cancer</i> , 2014, 111, 2379-2380.	2.9	3
137	Evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours. <i>Digestive and Liver Disease</i> , 2017, 49, 568-571.	0.4	3
138	Withholding the Introduction of Anti-Epidermal Growth Factor Receptor: Impact on Outcomes in RAS Wild-type Metastatic Colorectal Tumors: A Multicenter AGEO Study (the WAIT or ACT Study). <i>Oncologist</i> , 2020, 25, e266-e275.	1.9	3
139	1163P Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours (NETs): An international double-blind, placebo-controlled randomized phase II trial. <i>Annals of Oncology</i> , 2020, 31, S774.	0.6	3
140	A phase IIb of eryaspase in combination with gemcitabine or FOLFOX as second-line therapy in patients with metastatic pancreatic adenocarcinoma (NCT02195180).. <i>Journal of Clinical Oncology</i> , 2017, 35, e15718-e15718.	0.8	3
141	Trifluridine/tipiracil or regorafenib in refractory metastatic colorectal cancer patients: An AGEO prospective "real life" study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4036-4036.	0.8	3
142	Serum Pepsinogens Combined with New Biomarkers Testing Using Chemiluminescent Enzyme Immunoassay for Non-Invasive Diagnosis of Atrophic Gastritis: A Prospective, Multicenter Study. <i>Diagnostics</i> , 2022, 12, 695.	1.3	3
143	Prognosis and chemosensitivity of non-colorectal alimentary tract cancers with microsatellite instability. <i>Digestive and Liver Disease</i> , 2023, 55, 123-130.	0.4	3
144	Safety of FOLFIRI + Durvalumab + Tremelimumab in Second Line of Patients with Advanced Gastric Cancer: A Safety Run-In from the Randomized Phase II Study DURIGAST PRODIGE 59. <i>Biomedicines</i> , 2022, 10, 1211.	1.4	3

#	ARTICLE	IF	CITATIONS
145	Genetic variations of the A13/A14 repeat located within the EGFR3' untranslated region have no oncogenic effect in patients with colorectal cancer. <i>BMC Cancer</i> , 2013, 13, 183.	1.1	2
146	Selective Internal Radiation Therapy (SIRT) with Yttrium-90-glass-microspheres plus chemotherapy in first-line treatment of advanced cholangiocarcinoma (MISPHEC study). <i>Annals of Oncology</i> , 2017, 28, v242.	0.6	2
147	ARCAD-NADEGE cohort: Result of a small bowel adenocarcinomas prospective cohort. <i>Annals of Oncology</i> , 2018, 29, viii263.	0.6	2
148	OC-0284: First results of the French cohort ANABASE : treatment and outcome in non-metastatic anal cancer. <i>Radiotherapy and Oncology</i> , 2018, 127, S146.	0.3	2
149	Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI)-PRODIGE 62: A multicentre, randomised, non-comparative phase II study. <i>Digestive and Liver Disease</i> , 2020, 52, 347-350.	0.4	2
150	Maintenance treatment with fluoropyrimidine plus bevacizumab versus fluoropyrimidine alone after induction chemotherapy for metastatic colorectal cancer: The BEVAMAIN - PRODIGE 71 - (FFCD 1710) phase III study. <i>Digestive and Liver Disease</i> , 2020, 52, 1143-1147.	0.4	2
151	Real-world safety and effectiveness of regorafenib in metastatic colorectal cancer: the French CORRELATE cohort. <i>Future Oncology</i> , 2021, 17, 3343-3353.	1.1	2
152	Second-line chemotherapy for advanced biliary tract cancer after failure of gemcitabine plus platinum: Results of an AGEO multicenter retrospective study.. <i>Journal of Clinical Oncology</i> , 2014, 32, 4093-4093.	0.8	2
153	Characteristics, prognosis and treatments of 294 patients with poorly differentiated neuroendocrine carcinoma: The FFCD-GTE national cohort.. <i>Journal of Clinical Oncology</i> , 2015, 33, 4095-4095.	0.8	2
154	Prognosis and chemosensitivity of non-V600E BRAF mutations in metastatic colorectal carcinoma (mCRC): An AGEO French multicenter retrospective cohort.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3575-3575.	0.8	2
155	SOCRATE-PRODIGE 55 trial: A randomized phase II study to evaluate second-line ramucirumab alone or with paclitaxel in older patients with advanced gastric cancer. <i>Digestive and Liver Disease</i> , 2022, 54, 747-754.	0.4	2
156	Hyperkeratotic eczema of the nipple and areola associated with sorafenib treatment. <i>European Journal of Dermatology</i> , 2010, 20, 854-6.	0.3	2
157	2095 Survival benefit, safety, and prognostic factors for outcome with Regorafenib (RE) in patients (pts) with pretreated metastatic colorectal cancer (mCRC). Main analyses of the REBECCA study. <i>European Journal of Cancer</i> , 2015, 51, S360.	1.3	1
158	2090 Prognostic score (REGOSCORE) for survival after Regorafenib (RE) treatment for patients (pts) with pretreated metastatic colorectal cancer (mCRC). <i>European Journal of Cancer</i> , 2015, 51, S358.	1.3	1
159	Clinical characteristics of colorectal cancer patients with brain metastases: An "Association des Gastro-ŕologues Oncologues" (AGEO) multicenter study. <i>Annals of Oncology</i> , 2016, 27, vi196.	0.6	1
160	Folfox and intra-arterial DEBIRI as front-line treatment in patients with non resectable colorectal cancer liver metastases (FFCD 1201 phase II trial). <i>Annals of Oncology</i> , 2018, 29, viii153.	0.6	1
161	FOLFIRINOX in locally advanced (LA) and borderline resectable (BR) pancreatic adenocarcinoma: Update of the AGEO cohort. <i>Annals of Oncology</i> , 2019, 30, v260.	0.6	1
162	PRODIGE67_UCGI33 ARION: Association of radiochemotherapy and immunotherapy for the treatment of unresectable oesophageal cancer: A comparative randomized phase II trial. <i>Annals of Oncology</i> , 2019, 30, v322.	0.6	1

#	ARTICLE	IF	CITATIONS
163	46P [18F]2-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18FDG-PET/CT) in patients treated with immune checkpoint inhibitors (ICI) for microsatellite instability-high metastatic colorectal cancer (MSI mCRC). <i>Annals of Oncology</i> , 2020, 31, S1434.	0.6	1
164	PD-6 Gemcitabine + nab-paclitaxel or gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: A population-based, multicenter AGEO study. <i>Annals of Oncology</i> , 2020, 31, S213-S214.	0.6	1
165	Chemotherapy use in end-of-life digestive cancer patients: a retrospective AGEO observational study. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101709.	0.7	1
166	438P First line treatment patterns in BRAFV600E-mutant metastatic colorectal cancer patients (mCRC): The CAPSTAN European retrospective study. <i>Annals of Oncology</i> , 2021, 32, S553.	0.6	1
167	Masitinib plus irinotecan for second line treatment of esophagogastric adenocarcinoma: An open label phase Ib/II trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 4027-4027.	0.8	1
168	The consensus Immunoscore adapted to biopsies in patients with locally advanced rectal cancer: Potential clinical significance for a "Watch and Wait" strategy.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2628-2628.	0.8	1
169	RECIST and iRECIST criteria for the evaluation of nivolumab + ipilimumab combination in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI/dMMR) metastatic colorectal cancer (mCRC): Results of the GERCOR NIPICOL phase II study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 101-101.	0.8	1
170	Selective Internal Radiation Combined with Chemotherapy Maintains the Quality of Life in Intrahepatic Cholangiocarcinomas. <i>Current Oncology</i> , 2021, 28, 4530-4541.	0.9	1
171	337... Pembrolizumab in combination with xelox bevacizumab in patients with microsatellite stable (MSS) metastatic colorectal cancer and a high immune infiltrate: a proof of concept study. <i>FFCD 1703 POCHI</i> , 2020, , .		1
172	HSP110 as a Diagnostic but Not a Prognostic Biomarker in Colorectal Cancer With Microsatellite Instability. <i>Frontiers in Genetics</i> , 2021, 12, 769281.	1.1	1
173	AdvanTIG-203: A randomized phase 2 study comparing anti-TIGIT ociperlimab plus tislelizumab versus tislelizumab plus placebo as second-line treatment in patients with advanced or recurrent esophageal squamous cell carcinoma (ESCC) expressing programmed death-ligand 1 (PD-L1).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS370-TPS370.	0.8	1
174	Traitement des adénocarcinomes de l'œsophage. <i>Journal De Chirurgie Viscérale</i> , 2011, 148, 184-195.	0.0	0
175	2349 Phase 1b/2 study results for masitinib plus irinotecan in second-line treatment of esophagogastric adenocarcinoma. <i>European Journal of Cancer</i> , 2015, 51, S451.	1.3	0
176	End of life (EOL) chemotherapy (CT) in gastro-intestinal (GI) cancer patients (pts): A retrospective AGEO study. <i>Annals of Oncology</i> , 2016, 27, vi458.	0.6	0
177	Mutation in <i>BRAF</i> V600E. <i>JAMA Oncology</i> , 2017, 3, 1284.	3.4	0
178	Epidemiological study of histologically proven advanced hepatocholangiocarcinoma: An AGEO multicenter retrospective study. <i>Annals of Oncology</i> , 2017, 28, v241.	0.6	0
179	PRODIGE 50 - ASPIK French: French double blind randomised study of aspirin versus placebo in resected stage III or high risk stage II colon cancer with PIK3CA mutation. <i>Annals of Oncology</i> , 2017, 28, v206.	0.6	0
180	Withholding Anti-EGFR: Impact on outcome of RAS wild-type metastatic colorectal tumours (WAIT OR) Tj ETQq0 0 0 rgBT /Overlock 10 T	0.6	0

#	ARTICLE	IF	CITATIONS
181	Metastatic colorectal signet-ring cell carcinoma: Clinical, histological and molecular description from an AGEO French multicenter retrospective cohort. <i>Annals of Oncology</i> , 2018, 29, viii186.	0.6	0
182	Prediction of overall survival with 2nd-line (L2OS) chemotherapy (CT) in patients with advanced biliary tract cancer (aBTC): AGEO CT2BIL cohort update and international multicenter external validations. <i>Annals of Oncology</i> , 2018, 29, viii261-viii262.	0.6	0
183	Nal-iri/lv5-fu versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI-PRODIGE 62): A FFCD multicenter, randomized, phase II study. <i>Annals of Oncology</i> , 2019, 30, v324.	0.6	0
184	444P PRODIGE 25 (FFCD 11-01)-FOLFA: A randomized phase II trial evaluating aflibercept associated with LV5FU2 regimen as first-line treatment of non-resectable metastatic colorectal cancers. <i>Annals of Oncology</i> , 2020, 31, S430-S431.	0.6	0
185	P-247 Real-world clinical outcomes for third-line standard of care regimens in deficient mismatch repair or microsatellite instability-high metastatic colorectal cancer in France. <i>Annals of Oncology</i> , 2020, 31, S170-S171.	0.6	0
186	1454P PARAFIRIGAST: Paclitaxel/ramucirumab versus FOLFIRI as second line chemotherapy of metastatic gastric cancer: An AGEO multicenter comparative study with a propensity score analysis. <i>Annals of Oncology</i> , 2020, 31, S912-S913.	0.6	0
187	522TiP PRODIGE 71 - BEVAMAIN: A randomized phase III study comparing maintenance treatment with fluoropyrimidine + bevacizumab versus fluoropyrimidine after induction chemotherapy for a metastatic colorectal cancer. <i>Annals of Oncology</i> , 2020, 31, S460.	0.6	0
188	P-51 Baseline characteristics of patients enrolled in the CAPSTAN study: A European retrospective study in BRAFV600E-mutant metastatic colorectal cancer patients. <i>Annals of Oncology</i> , 2021, 32, S113.	0.6	0
189	Metastatic colorectal carcinoma with signet-ring cells: Clinical, histological and molecular description from an Association des Gastro-Entérologues Oncologues (AGEO) French multicenter retrospective cohort. <i>Digestive and Liver Disease</i> , 2021, , .	0.4	0
190	462P Heterogeneity of mismatch repair status between primary tumors and matched metastases in metastatic colorectal cancer. <i>Annals of Oncology</i> , 2021, 32, S563.	0.6	0
191	425P Cetuximab could be administered once every two weeks instead of once weekly. <i>Annals of Oncology</i> , 2021, 32, S547.	0.6	0
192	508TiP PRODIGE 68 - UCGI 38 - SOREGATT: A randomized phase II study comparing the sequences of regorafenib (reg) and trifluridine/tipiracil (t/t) after failure of standard therapies in patients (pts) with metastatic colorectal cancer (mCRC). <i>Annals of Oncology</i> , 2021, 32, S580-S581.	0.6	0
193	1472P Circulating tumor DNA in unresectable pancreatic cancer is a strong predictor of response to first-line therapy: The KRASCIPANC study. <i>Annals of Oncology</i> , 2021, 32, S1088.	0.6	0
194	Second-line chemotherapy by FOLFIRI in patients with advanced small bowel adenocarcinoma: A multicenter AGEO study. <i>Journal of Clinical Oncology</i> , 2010, 28, e14523-e14523.	0.8	0
195	Use of the essential autophagy protein beclin 1 to regulate DNA damage response and predict response to chemoradiation in rectal cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 492-492.	0.8	0
196	Regorafenib (REG) in the real-life setting: First results from a large French compassionate-use program in patients (pts) with previously treated metastatic colorectal cancer (mCRC). <i>Journal of Clinical Oncology</i> , 2014, 32, e14599-e14599.	0.8	0
197	Deletions in HSP110 and prognosis in colorectal cancers with microsatellite instability. <i>Journal of Clinical Oncology</i> , 2014, 32, e14577-e14577.	0.8	0
198	Abstract A114: Towards personalized cellular adoptive immunotherapy targeting tumor specific neo-antigens in microsatellite unstable colorectal cancers. , 2016, , .		0

#	ARTICLE	IF	CITATIONS
199	The ARCAD METACER national cohort study of brain metastases in gastro-intestinal cancers.. Journal of Clinical Oncology, 2016, 34, 2073-2073.	0.8	0
200	High intra- and inter-tumoral heterogeneity of <i>RAS</i> mutations in colorectal cancer.. Journal of Clinical Oncology, 2016, 34, 3577-3577.	0.8	0
201	Platinum rechallenge in patients with advanced biliary tract carcinoma (ABTC) after failure of gemcitabine (GEM)-platinum combination: A national AGEO retrospective study.. Journal of Clinical Oncology, 2016, 34, 4076-4076.	0.8	0
202	REMINET: A European, multicentre, PHASE II/III randomized double-blind, placebo-controlled study evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours.. Journal of Clinical Oncology, 2016, 34, TPS4148-TPS4148.	0.8	0
203	Three fluoropyrimidine-based regimens in second-line therapy following nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer: Efficacy and tolerance in clinical practice.. Journal of Clinical Oncology, 2018, 36, 370-370.	0.8	0
204	Prediction of overall survival with 2nd-line (L2OS) chemotherapy (CT) in patients (Pts) with advanced biliary tract cancer (aBTC): AGEO CT2BIL cohort update and international multicenter external validations.. Journal of Clinical Oncology, 2018, 36, e16119-e16119.	0.8	0
205	Withholding anti-EGFR, the impact on outcome in RAS wild-type metastatic colorectal tumors (WAIT) Tj ETQq1 1 0,784314 rgBT /Over	0,8	0
206	BIONADEGE: Genomic profiling of small bowel adenocarcinoma from the NADEGE prospective cohort.. Journal of Clinical Oncology, 2019, 37, 4140-4140.	0.8	0
207	OC-0270 Final results of the French national cohort ANABASE : treatment and outcome in anal cancer. Radiotherapy and Oncology, 2022, 170, S226-S227.	0.3	0
208	MO-0226 Clinical outcomes of HIV-positive patients with anal cancer in the ANABASE multicentric cohort. Radiotherapy and Oncology, 2022, 170, S185-S186.	0.3	0